MOUNTAIN VIEW, Calif., March 31, 2011 /PRNewswire/ — VIVUS,
Inc. (Nasdaq:
VVUS) today announced that data on QNEXA®, its
investigational drug candidate, will be featured in a poster
presentation at the 60th Annual Scientific Meeting of The American
College of Cardiology, being held April 2-5, 2011 in New Orleans,
Louisiana.
Following are details about the poster presentation:
The poster will be presented in Hall F of The Ernest N. Morial
Convention Center in New Orleans, Louisiana on Sunday, April 3,
2011, 1:45 PM to 4:45 PM (Session 1048)
The Presenter, Dr. Michael H. Davidson, will be at the poster
from 3:30 PM to 4:45 PM. Presenter:
Michael Davidson, MD, FACC, FACP, FNLAAuthors:
Davidson, Bowden, Day Title:
Weight Loss and Cardiovascular Risk Reduction Over Two Years
with Controlled-Release Phentermine-Topiramate (Presentation Number
1048-293)About QNEXA Controlled Release CapsulesQNEXA
[kyoo-nek-suh] is an investigational drug candidate being
developed to address weight loss, type 2 diabetes and obstructive
sleep apnea. QNEXA is a once-a-day, proprietary, oral,
controlled-release formulation of low-dose phentermine and
topiramate, which is designed to decrease appetite and increase
satiety (the sense of feeling full), the two main mechanisms that
impact eating behavior. In phase 2 and 3 clinical data to date,
patients taking QNEXA have demonstrated statistically significant
weight loss, glycemic control, and improvement in cardiovascular
risk factors, when used in combination with a diet and lifestyle
modification program.
About VIVUS VIVUS is a biopharmaceutical company developing
therapies to address obesity, sleep apnea, diabetes and male sexual
health. The company’s lead product in clinical development,
QNEXA®, has completed phase 3 clinical trials for the treatment
of obesity and is currently
‘/>”/>
SOURCE
